Merck KGaA’s Strategic SpringWorks Acquisition Yields Key European Approvals
Published on 09/14/2025 at 11:27 | Redaktion boerse-global.de
Merck KGaA’s recent $3.9 billion acquisition of SpringWorks Therapeutics is demonstrating immediate strategic value, with European regulators granting marketing authorization for two key therapies that significantly bolster the company’s presence in the rare disease market.
The European Commission granted approval on August 18, 2025, for OGSIVEO® (nirogacestat) as a treatment for adults with progressing desmoid tumors. This decision followed the conditional marketing authorization awarded on July 18, 2025, for EZMEKLY® (mirdametinib) targeting neurofibromatosis type 1-associated plexiform neurofibromas in patients aged two years and older.
These regulatory successes stem from positive assessments issued by the European Medicines Agency’s CHMP committee in May and June of 2025. Both therapeutic options had previously received approval from the U.S. Food and Drug Administration.
Strategic... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
